Illumina And Labcorp Expand Collaboration To Advance Precision Oncology With NGS, Liquid Biopsy And New Distributed Biomarker Testing

Illumina, Inc. and Labcorp have expanded their collaboration to enhance precision oncology through next-generation sequencing (NGS) and liquid biopsy solutions. The partnership will focus on developing new tests, promoting equitable access to cancer biomarker testing, and exploring co-commercialization of Labcorp's FDA-authorized liquid biopsy assay and Illumina's FDA-approved TruSight Oncology test. This initiative aims to bridge testing gaps and improve access to advanced biomarker testing for cancer patients.